Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitors

This page shows the latest SGLT2 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The CHMP decision is based on the results of the CANVAS programme, the largest completed CV outcomes trial to date for any of the SGLT2 inhibitors. ... The first SGLT2 inhibitor to gain this EU label update was Boehringer and Lilly’s.

Latest news

More from news
Approximately 3 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. “ ... Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including

  • Pharma deals during April 2013 Pharma deals during April 2013

    SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels. ... Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics